105.14
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $105.14, with a volume of 153.42K.
It is down -2.30% in the last 24 hours and down -13.98% over the past month.
See More
Previous Close:
$107.62
Open:
$105.55
24h Volume:
153.42K
Relative Volume:
1.47
Market Cap:
$2.11B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
41.89
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-5.85%
1M Performance:
-13.98%
6M Performance:
+5.05%
1Y Performance:
+43.83%
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LGND
Ligand Pharmaceuticals Inc
|
105.14 | 2.11B | 152.42M | 45.24M | 6.97M | 2.51 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-03-24 | Initiated | Oppenheimer | Outperform |
Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
Apr-14-21 | Resumed | Stephens | Overweight |
Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
Oct-06-20 | Initiated | Barclays | Overweight |
Mar-24-20 | Downgrade | Argus | Buy → Hold |
Mar-10-20 | Initiated | Guggenheim | Neutral |
Feb-06-20 | Initiated | The Benchmark Company | Buy |
Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
Jun-11-19 | Initiated | Barclays | Equal Weight |
May-03-19 | Reiterated | H.C. Wainwright | Buy |
Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
Sep-11-18 | Reiterated | Argus | Buy |
Aug-17-18 | Initiated | Goldman | Neutral |
Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
Jun-21-18 | Initiated | Argus | Buy |
Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
Sep-05-17 | Resumed | H.C. Wainwright | Buy |
Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-11-16 | Initiated | Sidoti | Buy |
Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Teacher Retirement System of Texas Boosts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
HighTower Advisors LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Raymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire
Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World
US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World
Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus
Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com
Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
LGND: First Steps into Cell & Gene Therapy - Research Tree
Ligand CEO and CFO Heading to Miami: Key Investor Access Points for LGND Shareholders - StockTitan
Ligand to Participate in March Investor Conferences - Yahoo Finance
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
Principal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3%Should You Buy? - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings Results - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Ligand Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
New York State Common Retirement Fund Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Ligand: Q4 Earnings Snapshot - mySA
Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set - Marketscreener.com
Ligand Pharmaceuticals Incorporated Reaffirms the Earnings Guidance for the Year 2025 - Marketscreener.com
Ligand Pharma Slips To Loss In Q4; Confirms FY25 OutlookUpdate - Nasdaq
LIGAND PHARMACEUTICAL Earnings Results: $LGND Reports Quarterly Earnings - Nasdaq
Ligand Pharmaceuticals Q4 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Ligand: Q4 Earnings Snapshot -February 27, 2025 at 07:24 am EST - Marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals, Posts Q4 Revenue $42.8M, vs. FactSet Est of $39.0M - Marketscreener.com
Ligand Pharmaceuticals Inc Q4 Earnings Summary - Nasdaq
Ligand Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stake Reduced by Rhumbline Advisers - Defense World
Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need T - GuruFocus.com
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):